Summary
RAPT Chart
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
OrbiMed Advisors increased its position in RAPT Therapeutics by 556,273 shares during the fourth quarter; the estimated trade size was $17.28 million based on quarterly average pricing. The quarter-end value of the RAPT stake rose by $27.62 million, reflecting both additional shares and stock price appreciation.
RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RAPT Therapeutics, Inc. (RAPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices
RAPT Therapeutics is upgraded to a 'Buy' due to promising pipeline progress and attractive valuation after a significant share price decline. Ozureprubart, RAPT's lead candidate, showed favorable phase 2 data in chronic spontaneous urticaria, with potential for less frequent dosing than competitors. RAPT's strong cash position, bolstered by a $250 million offering, provides operational runway, but future cash burn for pivotal trials remains a risk.
Rapt Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| LP Li Peng China Universal Asset Management Co. Ltd. | 4,515 | $152.92 | $135.45 | -$17.47 | -11.42% |
| KJ Ken Joseph Braidwel LLP | 929,694 | $31.49M | $31.49M | -$0.19 | - |
| DP Drew Phillips Fortitude Family Office LLC | 63 | $1,625 | $1,624.77 | -$0.23 | -0.01% |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 16 | $405 | $404.96 | -$0.04 | -0.01% |
Rapt Therapeutics, Inc. (RAPT) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Rapt Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Brian Russell Wong M.D., Ph.D. CEO | NASDAQ (NMS) Exchange | 75382E109 CUSIP |
| United States Country | 60 Employees | - Last Dividend | 17 Jun 2025 Last Split | 31 Oct 2019 IPO Date |
Overview
RAPT Therapeutics, Inc. is a pioneering clinical-stage immunology-based biopharmaceutical company that is at the forefront of developing oral small molecule therapies. With a focus on addressing the unmet needs of patients battling oncology and inflammatory diseases within the United States, RAPT Therapeutics is dedicated to advancing the field of medicine through its innovative research and development efforts. Initially established as FLX Bio, Inc., the company underwent a strategic rebranding to RAPT Therapeutics, Inc. in May 2019, signaling its deepened commitment to exploring therapeutic possibilities and enhancing patient care. Founded in 2015 and having its headquarters in South San Francisco, California, RAPT Therapeutics operates under the umbrella of Bristol-Myers Squibb Company, marking its stature as a noteworthy subsidiary within the pharmaceutical industry.
Products and Services
-
Zelnecirnon (RPT193)
As RAPT Therapeutics' leading inflammation drug candidate, zelnecirnon, scientifically referred to as RPT193, represents a significant advancement in the treatment of inflammatory diseases. This innovative oral small molecule therapy functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. Its mechanism of action is specifically designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues, thereby offering a novel approach to mitigating the effects of chronic inflammatory conditions. The drug's focus on targeting the root causes of inflammation at the cellular level underscores RAPT Therapeutics' commitment to addressing complex immunological challenges through targeted therapy.
-
Tivumecirnon (FLX475)
Marking its prominence in RAPT Therapeutics' oncology portfolio, tivumecirnon, known as FLX475, is the company's premier oncology drug candidate. This oral small molecule therapy shares its CCR4 antagonist classification with its counterpart in the inflammation domain, zelnecirnon, but is uniquely tailored for combating cancer. Tivumecirnon is currently undergoing a Phase 1/2 clinical trial, where its efficacy as both a monotherapy and in combination with pembrolizumab is under investigation in patients with advanced cancer. This comprehensive clinical trial aims to validate tivumecirnon's potential to revolutionize cancer treatment through its targeted, minimally invasive approach, highlighting RAPT Therapeutics' dedication to pioneering in the field of cancer therapy.
